Peter Sguigna, M.D.

Peter O'Donnell Jr. Brain Institute

Neurology
Multiple Sclerosis
Optic neuritis

Biography

Peter Sguigna, M.D., is an Assistant Professor in the Department of Neurology at UT Southwestern Medical Center. He specializes in the treatment of multiple sclerosis, optic neuritis, and neurological vision loss.

Dr. Sguigna earned his medical degree at UT Southwestern, where he also completed a residency in neurology and a fellowship in multiple sclerosis. Certified by the American Board of Psychiatry and Neurology, he joined the UT Southwestern faculty in 2020.

The author of numerous articles, Dr. Sguigna’s research interests include the advanced diagnostic imaging of neuro-ophthalmological disorders, as well as unraveling the neuro-retinal circuitry in neuroimmunological diseases. He actively works on better ways to distinguish these disorders using noninvasive technology. He uses specialized testing to gain insight into some of the most disabling symptoms for patients with multiple sclerosis and coordinates clinical trials for better treatment of the disease.

Dr. Sguigna is a member of the American Academy of Neurology and the North American Neuro-Ophthalmology Society. He is an ad-hoc reviewer for numerous journals.

Education & Training

Medical School - UT Southwestern Medical School (2010-2014)
Residency - UT Southwestern Medical Center (2014-2018), Neurology
Fellowship - UT Southwestern Medical Center (2018-2020), Multiple Sclerosis

Professional Associations & Affiliations

American Academy of Neurology
North American Neuro-Ophthalmology Society

Honors & Awards

President’s Research Council 2020-2021
Scholar Award 2018-2020, Center for Translational Medicine
Best Fellow Poster Award 2019, Neurology Research Day
Educational Travel Grant 2019, Americas Committee for Treatment and Research in Multiple Sclerosis
Early Stage Investigator Award 2018-2019, NeuroNEXT
Best Poster Award 2017, UTSW Research Day Committee

Books & Publications

Publications
- Correction: Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials (Journal of Nanobiotechnology, (2023), 21, 1, (478), 10.1186/s12951-023-02236-z)
  Ren J, Dewey RB, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB, Greenberg BM Journal of Nanobiotechnology 2024 Dec 22
- Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design
  Sguigna PV, Hussain RZ, Okai A, Blackburn KM, Tardo L, Madinawala M, Korich J, Lebson LA, Kaplan J, Salter A, Manouchehri N, Stuve O Therapeutic Advances in Neurological Disorders 2024 Jan 17
- Evidence of brain target engagement in Parkinson’s disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials
  Ren J, Rynders A, Evan J, Evan J, Ligozio S, Ho KS, Sguigna PV, Glanzman R, Hotchkin MT, Dewey RB, Greenberg BM Journal of Nanobiotechnology 2023 Dec 21
- Subclinical optic neuritis in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease
  Nguyen L, Wang CX, Conger DL, Sguigna PV, Singh S, Greenberg BM Multiple Sclerosis and Related Disorders 2023 Aug 76
- Disease associations of excessive daytime sleepiness in multiple sclerosis: A prospective study
  Sguigna PV, Toranian S, Tardo LM, Blackburn KM, Horton LA, Conger D, Meltzer E, Hogan RN, McCreary M, Zee PC, Takahashi JS, Greenberg BM Multiple Sclerosis Journal - Experimental, Translational and Clinical 2023 Jan 9
- A narrative review of neuro-ophthalmologic disease in African Americans and Hispanics with multiple sclerosis
  Tardo L, Salter A, Truong-Le M, Horton L, Blackburn KM, Sguigna PV Therapeutic Advances in Chronic Disease 2023 Jan 14
- A cross-sectional natural history study of aspartylglucosaminuria
  Goodspeed K, Horton DK, Lowden A, Sguigna PV, Booth T, Wang ZJ, Edgar VB JIMD Reports 2022 Sep 63 425-433
- The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives
  Hussain RZ, Sguigna PV, Okai A, Wright C, Madinawala M, Bass AD, Cutter GR, Manouchehri N, Stuve O Journal of Central Nervous System Disease 2022 Aug 14
- Application of the International Interocular Difference Thresholds into Practice: Localising the Patient Experience
  Sguigna PV, Tardo LM, Blackburn KM, Horton LA, Conger DL, Hogan RN, McCreary MC, Greenberg BM Neuro-Ophthalmology 2022 46 375-382
- Asymptomatic retinal vasculopathy in neuropsychiatric systemic lupus erythematosus
  Sguigna PV, Tardo L, Conger D, Hogan R, Greenberg BM Journal of the Neurological Sciences 2021 Nov 430
- Utilization of Visual Acuity Retroilluminated Charts for the Assessment of Afferent Visual System Dysfunction in a Pediatric Neuroimmunology Population
  Sguigna PV, McCreary MC, Conger DL, Graves JS, Benson LA, Waldman AT, Greenberg BM Journal of Neuro-Ophthalmology 2021 Mar 41 19-23
- Utilization of video oculography to quantify oculomotor dysfunction in anti-DPPX encephalitis: A case study
  Blackburn K, Vernino S, Sguigna P Multiple Sclerosis and Related Disorders 2020 Nov 46
- Cataclysmically disseminating neurologic presentation in an immunosuppressed lupus patient: From the National Multiple Sclerosis Society Case Conference Proceedings
  Perrone CM, Lisak RP, Meltzer EI, Sguigna P, Tizazu E, Jacobs D, Melamed E, Lucas A, Freeman L, Pardo G, Goodman A, Fox EJ, Costello K, Parsons MS, Zamvil SS, Frohman EM, Frohman TC Neurology: Neuroimmunology and NeuroInflammation 2019 Jul 6
- Atypical Anti-MOG syndrome with aseptic meningoencephalitis and pseudotumor cerebri-like presentations
  Narayan RN, Wang C, Sguigna P, Husari K, Greenberg B Multiple Sclerosis and Related Disorders 2019 Jan 27 30-33
- Retinal architecture and melanopsin-mediated pupillary response characteristics: A putative pathophysiologic signature for the retino-hypothalamic tract in multiple sclerosis
  Meltzer E, Sguigna PV, Subei A, Beh SC, Kildebeck E, Conger D, Conger A, Lucero M, Frohman BS, Frohman AN, Saidha S, Galetta S, Calabresi PA, Rennaker R, Frohman TC, Kardon RH, Balcer LJ, Frohman E JAMA neurology 2017 May 74 574-582
- Managing Disability in Progressive Multiple Sclerosis
  Dubey D, Sguigna P, Stüve O Current Treatment Options in Neurology 2016 Jun 18
- Acute relapse after initiation of Siponimod in a patient with secondary progressive MS
  Hussain R, O’Leary S, Pacheco FM, Zacharias TE, Litvak P, Sguigna P, Marder E, Kia K, Kooner K, Stüve O Journal of neurology 2016 Mar 263 606-610
- Sterol-induced degradation of HMG CoA reductase depends on interplay of two Insigs and two ubiquitin ligases, gp78 and Trc8
  Jo Y, Lee PC, Sguigna PV, DeBose-Boyd RA Proceedings of the National Academy of Sciences of the United States of America 2011 Dec 108 20503-20508
- Membrane-associated ubiquitin ligase complex containing gp78 mediates sterol-accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme a reductase
  Jo Y, Sguigna PV, Debose-Boyd RA Journal of Biological Chemistry 2011 Apr 286 15022-15031

Research

Clinical trials
Medical devices
MOG antibody associated disorders
Multiple sclerosis
Neuro-ophthalmology
Neuromyelitis optica spectrum disorder
Optic neuritis
Visual dysfunction

Clinical Focus

Multiple Sclerosis
Optic neuritis
Vision Loss